AER final rule for application OTCs
This article was originally published in The Tan Sheet
Executive Summary
FDA finalizes its interim final rule requiring application, or non-monograph, OTC products, and all Rx drugs to include toll-free numbers for reporting adverse events on packaging, effective Nov. 28. The rule, which also applies to private-label products, was mandated by the Food and Drug Administration Amendments Act of 2007 (1"The Tan Sheet" Jan. 21, 2008, p. 13). According to an Oct. 28 Federal Register notice, labels should explain the numbers are for AE reporting only. The compliance deadline is July 1, 2009
You may also be interested in...
FDAAA Requires Toll-Free Number For Side Effect Reports On Application OTCs
A rule mandated by the FDA reauthorization Congress passed in 2007 that requires a toll-free number for reporting side effects on packaging for non-monograph OTC products and all Rx drugs went into effect Jan.1, but the agency likely will not enforce it until 2009
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.